ACE2 and COVID-19: In this context it is to mention that, despite low ACE2 expression, patients with CVDs have still higher COVID-19 mortality, caused probably by the imbalance between ADAM17 expression required for cleavage of ACE2 for virus uptake, and TMPRSS2, which is required for spike glycoprotein priming.